1. <progress id="voycx"></progress>
    1. A POWERFUL RESEARCH AND
      DEVELOPMENT ENGINE

      Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

      Interact with the Regeneron Pipeline

      Select Therapeutic Area(s):
      Select Phase(s):
      Select Collaborator(s):

      Displaying item(s)

      Clear Filters

      Phase 1 trials Phase 1 trials
      • CEMIPLIMAB*
        PD-1 Antibody Cancer
      • REGN3767
        LAG-3 Antibody Cancer
      • REGN1979
        CD20xCD3 Antibody Cancer
      • REGN4018*
        MUC16xCD3 Antibody Cancer
      • REGN5093
        METxMET Antibody Cancer
      • REGN5458*
        BCMAxCD3 Antibody Cancer
      • REGN5459*
        BCMAxCD3 Antibody Cancer
      • REGN5678
        PSMAxCD28 Antibody Cancer
      • REGN5713-5714-5715
        Betv1 Antibody Birch Allergy
      Phase 2 trials Phase 2 trials
      • CEMIPLIMAB*
        PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
      • AFLIBERCEPT
        VEGF Trap High-dose for wet age-related macular degeneration (AMD)
      • REGN1979
        CD20xCD3 Antibody Relapsed/refractory follicular lymphoma, non-Hodgkin lymphomas, diffuse large B-cell lymphoma
      • DUPILUMAB*
        IL-4R Antibody Grass allergy, peanut allergy
      • SARILUMAB*
        IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
      • REGN1908-1909
        Fel d 1 Antibody Cat allergy
      • REGN3500*
        IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis
      • REGN5069
        GFRα3 Antibody Osteoarthritis knee pain
      • REGN4461
        LEPR Antibody Generalized lipodystrophy
      • GARETOSMAB
        Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
      • EVINACUMAB
        ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
      • POZELIMAB
        C5 Antibody Paroxysmal nocturnal hemoglobinuria
      Phase 3 trials Phase 3 trials
      • AFLIBERCEPT
        VEGF Trap Retinopathy of Prematurity (ROP)
      • ALIROCUMAB*
        PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics
      • CEMIPLIMAB*
        PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)
      • REGN-EB3
        Ebola Virus Antibody Ebola virus infection
      • DUPILUMAB*
        IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatrics, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), prurigo nodularis, bullous pemphigoid, chronic spontaneous urticaria
      • SARILUMAB*
        IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis
      • EVINACUMAB
        ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
      • FASINUMAB?
        NGF Antibody Chronic pain from osteoarthritis of the knee or hip

      No results found, please adjust your filter selection and try again.

      * In collaboration with Sanofi

      ? In collaboration with Teva and Mitsubishi Tanabe

      This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

      樱桃福利入口